These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 2122421

  • 1. Aldose reductase inhibitors.
    Kirchain WR, Rendell MS.
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [Abstract] [Full Text] [Related]

  • 2. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S.
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [Abstract] [Full Text] [Related]

  • 3. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N, Sakamoto N.
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract] [Full Text] [Related]

  • 4. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M, Sharma YR, Cotlier E, Hollander JD.
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB.
    Asia Pac J Clin Nutr; 2008 Oct; 17(4):558-65. PubMed ID: 19114390
    [Abstract] [Full Text] [Related]

  • 7. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ, Abobo CV, Carter BL, Ball DW.
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Microvascular complications of diabetes.
    He Z, King GL.
    Endocrinol Metab Clin North Am; 2004 Mar; 33(1):215-38, xi-xii. PubMed ID: 15053904
    [No Abstract] [Full Text] [Related]

  • 12. [The role of polyol pathways in formation of diabetic cataracts].
    Sabasiński K, Andrzejewska-Buczko J.
    Klin Oczna; 1997 Mar; 99(6):401-4. PubMed ID: 9685789
    [Abstract] [Full Text] [Related]

  • 13. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M.
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [Abstract] [Full Text] [Related]

  • 14. Aldose reductase inhibitors and diabetic complications.
    Raskin P, Rosenstock J.
    Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
    [No Abstract] [Full Text] [Related]

  • 15. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S, Buyukbingol E.
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Correction of diabetic neuropathies using aldose reductase inhibitors and pikamilon].
    Kuchmerovskaia TM, Parkhomets PK, Donchenko GV, Obrosova IG, Klimenko AP, Kuchmerovskiĭ NA, Pakirbaeva LV, Efimov AS.
    Vopr Med Khim; 1998 Aug; 44(6):559-64. PubMed ID: 10599142
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.